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Vascular access for chronic hemodialysis has clas-
sically been initiated by the creation of a primary
radial artery–to–cephalic vein arteriovenous fistula
(RCAVF). Since its first description by Brescia et al.1
in 13 patients with end-stage renal failure caused by
chronic glomerulonephritis and polycystic kidney
disease, there is no question that for the majority of
patients who start hemodialysis RCAVF remains the
procedure of choice. Between 1977 and 1989, pub-
lished reports of 823 RCAVFs have detailed a 2-year
primary patency rate of 67%, with a combined early
thrombosis or nonmaturation rate between 11% and
27%.2-5 Interestingly, only 6% to 13% of patients had
a history of diabetes mellitus. In these patients, our
clinical impression had been that when RCAVFs are
created the majority do not mature to the point of
cannulation.
Upper-arm brachiocephalic arteriovenous fistulas
(BCAVFs) have recently been reported in three large
series as secondary procedures after failure of distal
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Purpose: Primary radiocephalic arteriovenous fistulas (RCAVFs) have classically been
used for the initiation of dialysis. If a suitable forearm cephalic vein can be demonstrat-
ed, it is used to construct such a fistula. However, we have noted a tendency for RCAVF
in patients with a history of diabetes mellitus (type I and type II) to remain patent but
not mature to the point of cannulation. Therefore, the present study was undertaken.
Methods: Fifty-eight consecutive patients with diabetes who required initial access for
hemodialysis at an urban medical center and tertiary Veterans Medical Center under-
went creation of an RCAVF (n = 10), brachiocephalic arteriovenous fistula (BCAVF; n
= 22), or transposed basilic vein arteriovenous fistula (TBAVF; n = 26). The vein used
was determined by physical examination with tourniquet compression. If neither fore-
arm or upper-arm cephalic veins were 2 mm in diameter, a TBAVF was created after
venography. Patency was determined by Kaplan-Meier estimate; differences between
groups were assessed by Fisher’s exact test.
Results: The 70% rate of nonmaturation of RCAVFs was significantly greater than the
27% rate for BCAVFs and 0% for TBAVFs (p < 0.05). The 33% cumulative primary
patency rate at 18 months for RCAVFs was significantly less than 78% for BCAVFs and
79% for TBAVFs (p < 0.001). Within and between groups, there were no significant dif-
ferences in age, gender, aspirin use, history of congestive heart failure, erythropoietin
use, hematocrit level, history of peripheral vascular disease, or mortality rate.
Conclusions: In patients with renal failure and a history of diabetes, both primary
BCAVFs and TBAVFs demonstrate significantly greater maturation and increased pri-
mary cumulative patency rates compared with RCAVFs; therefore, these autogenous
conduits are considered to be optimal in this group of patients. Whether the discrepan-
cy in lower-arm vein maturation is a result of a lack of compensatory increase in radial
arterial flow or an intrinsic defect in the lower-arm cephalic vein is currently under
investigation. (J Vasc Surg 1998;27:154-7.)
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sites.6-8 Collectively, 306 BCAVFs had a 1-year pri-
mary patency rate between 54% and 90%.
Unfortunately, a history of diabetes was not report-
ed in two series and was present in only 16% of
patients in the most recent series.6 Interestingly,
BCAVF was first reported as a primary access proce-
dure in nine patients with occluded radial arteries;
however, a history of diabetes was not documented.9
Transposed basilic vein arteriovenous fistulas
(TBAVF) have also been considered secondary pro-
cedures after exhaustion of distal sites. Collectively,
130 TBAVFs have been created in children and
adults who required chronic hemodialysis.10-13 The
earliest series included 23 TBAVFs as the initial pro-
cedure in 21 patients, none of whom had diabetes.
In the subsequent series, creation of TBAVFs fol-
lowed failure of more distal access procedures in the
majority of patients. Unfortunately, a history of dia-
betes was not reported in these series.
The present study was undertaken to compare
the degree of maturation and primary patency rate
of primary RCAVFs, BCAVFs, and TBAVFs in
patients with a history of diabetes mellitus.
MATERIALS AND METHODS
Patient information. From August 1992
through December 1996, a total of 58 autogenous
arteriovenous fistulas were created in 18 women and
40 men with a mean age of 61 years (range, 35 to
85 years). All patients had a history of either type I
or type II diabetes mellitus.
Seven patients had undergone initial creation of
an RCAVF that failed to mature and underwent cre-
ation of a BCAVF (n = 3) or TBAVF (n = 4). The
remaining 44 patients had not undergone a previous
access procedure.
Technique of RCAVF creation. RCAVF were
created after documentation of a negative Allen test
result and demonstration of a cephalic vein of at least
2 mm diameter with tourniquet compression at the
antecubital fossa. With the patient under local anes-
thesia, a longitudinal incision was made midway
between the cephalic vein and radial artery.
Anastomosis was performed in an end-to-side fash-
ion using 6-0 polypropylene suture in a continuous
fashion. After arterialization, cephalic vein branches
were ligated with 3-0 silk suture via separate inci-
sions. Fistulas were allowed to mature for a mini-
mum of 4 weeks and a maximum of 16 weeks before
cannulation.
Technique of BCAVF creation. BCAVFs were
created after documentation of a negative Allen test
result and demonstration of a cephalic vein of at least
2 mm diameter with tourniquet compression at the
axillary fold. Surgical exposure and cephalic vein mobi-
lization with the patient under local anesthesia have
been previously described.9 However, we have limited
the length of the arteriotomy to 4 mm to prevent sub-
sequent steal phenomenon.2 Once again, fistulas were
allowed to mature for a minimum of 4 weeks and a
maximum of 16 weeks before cannulation.
Technique of TBAVF creation. Patients who
did not have an adequate upper-arm cephalic vein
underwent either preoperative or intraoperative
venography to demonstrate patent basilic and
brachial veins, because after TBAVF creation the lat-
ter would serve as the primary venous drainage of
the forearm.
The surgical technique used represents a modifi-
cation of previous techniques.11-13 All TBAVFs were
created with the patient under general anesthesia,
with a medial longitudinal incision placed directly
anterior to the basilic vein, as demonstrated on
venography.
After mobilization of the basilic vein to the level
of the antecubital veins, the brachial artery was dis-
sected from within the longitudinal incision, avoid-
ing a second incision as has been previously
described. A commercially available tunneling device
with interchangeable heads (Impra, Inc., Tempe,
Ariz.) was used to create an 8 mm subdermal tunnel.
With the tunneling device in place, the distal ante-
cubital vein in continuity with the basilic vein was
transected. The basilic vein was irrigated gently with
normal saline solution containing heparin (5000
U/L) and occluded with a plastic bulldog clamp.
The basilic vein was then retracted from beneath the
lateral cutaneous nerve. The 8 mm tunneling head
was replaced with the 2 mm head, and the vein was
secured with a 2-0 silk suture. The tunneling device
was then removed from the distal incision. In this
fashion, the basilic vein was transposed with gentle
distension, avoiding axial rotation.
The brachial arteriotomy was limited to 4 mm,
and anastomosis was created using a single 6-0
polypropylene suture in continuous fashion.
TBAVFs were allowed a minimum of 3 weeks and a
maximum of 6 weeks to mature before cannulation.
Statistical analysis. Survival and cumulative pri-
mary patency estimates were determined by the
Kaplan-Meier technique (Lifetest, SAS, licensed to
Boston University). Comparison of estimates was
performed with the log-rank test. The Cox propor-
tional hazards model was used to construct univari-
ate analysis, and c2 and Fisher’s exact tests were used
to compare categorical variables.
RESULTS
For the entire series, there were no operative
deaths or fistula thrombosis. The follow-up interval
extended to 50 months (mean, 25 months; median,
19 months). A wound infection occurred in one
patient with a TBAVF, for an overall incidence of
1.7%. This infection was treated conservatively with
culture-specific oral antibiotics and daily wound care
and resulted in salvage of the fistula. The 70% rate of
nonmaturation for RCAVFs occurred despite obser-
vation up to 16 weeks. This rate was significantly
greater than that for BCAVFs and TBAVFs (Table
I). The seven patients with nonmaturing RCAVFs
subsequently underwent creation of a BCAVF (n =
3) or TBAVF (n = 4), whereas the six patients with
nonmaturing BCAVFs underwent revision to a poly-
tetrafluoroethylene (PTFE) brachial artery–to–axil-
lary vein arteriovenous fistula.
Primary patency estimates indicated a significant
advantage for BCAVFs and TBAVFs at 18 months
when compared with RCAVFs (p < 0.01). There was
no significant difference between patency estimates
for BCAVFs and TBAVFs.
DISCUSSION
Traditionally, the initial approach to vascular
access for dialysis has been the creation of an
RCAVF, followed by use of more proximal sites.
This strategy maximizes the longevity of available
fistulas for long-term hemodialysis. In the present
study, 10 patients with a history of diabetes under-
went creation of an RCAVF, with nonmaturation of
the fistula in more than two thirds and an 18-month
cumulative primary patency rate of 30%. Although
this number of patients is small, a larger series of pri-
mary radiocephalic fistulas in patients with diabetes
has not been reported. Given these results, it is dif-
ficult to justify subjecting additional patients to
RCAVF creation when options for durable alterna-
tive autogenous fistulas exist.
All patients had a history of diabetes and
required exogenous insulin therapy before the devel-
opment of end-stage renal failure. Although diabetes
mellitus is a very well-described cause of glomeru-
losclerosis, a cause-effect relationship in patients
who have end-stage renal failure is problematic. In
the majority of cases, a biopsy of the atrophic kidney
is of little value in differentiating the cause of renal
failure. Recently, the ability to differentiate type I, or
insulin-dependent, and type II diabetes using mono-
clonal antibody determination of antiislet autoanti-
bodies has been demonstrated.14,15 Such determina-
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tions may allow for more precise classification of
patients with diabetes who require hemodialysis for
end-stage renal failure.
The reasons for nonmaturation of RCAVFs in
patients with diabetes remain to be defined. The
diameter of the vein at the site of anastomosis, in the
present series and in patients without diabetes, was
at least 2 mm in all cases of forearm and upper-arm
primary arteriovenous fistulas and TBAVFs.
Therefore, a smaller-diameter vein could not be
implicated in nonmaturing RCAVFs.
It is generally accepted that in patients with a his-
tory of diabetes medial calcification develops in dis-
tal upper and lower extremity arteries. Although
such calcification can be demonstrated with duplex
scanning using a 7.5 MHz probe, demonstration of
circumferential calcification, which may be hemody-
namically significant, remains problematic. In addi-
tion, the proximal radial and distal brachial arteries
are difficult to image because of their anatomic
course. Lastly, intraoperative assessment of the
degree of calcification was limited to the 3 to 4 cm
segment of artery that was mobilized to create the
end-to-side anastomosis. In no case was a calcified
vessel encountered that precluded creation of the
anastomosis.
It is well established that hemodynamic changes
must occur to sustain, and increase flow through, an
arteriovenous fistula. Both antegrade and retrograde
flow increase toward the low-resistance arteriove-
nous fistula, resulting in arterial dilatation. Because
Table I. Characteristics of 58 autogenous arteri-
ovenous fistulas created for chronic hemodialysis in
51 patients with diabetes
Upper arm
Forearm BCAVF TBAVF 
(RCAVF; n = 10) (n = 22) (n = 26)
64 62 59
3:7 5:18 10:16
70 27* 0
11 22 20
33 78† 79†
— 13 15
33 10 25
67 44 50
67 78 80
22 56 52
28 ± 3 28 ± 2 29 ± 3
*p < 0.05.
†p < 0.01.
PVD, Peripheral vascular disease.
Mean age (yr)
Female:male
Nonmaturation rate (%)
Mortality rate (%)
Cumulative patency rate
(18-month; %)
Prior distal RCAVF (%)
Aspirin (%)
Congestive heart failure
(%)
Erythropoietin (%)
History of PVD (%)
Hematocrit level (%)
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patients who have a history of diabetes commonly
display medial calcification, this may prevent such
dilatation and increased fistula blood flow.
One explanation may be a structural defect in the
forearm cephalic vein—although one would expect
the same venous architecture in the upper-arm
vein—which matures in the majority of BCAVFs.
This may also explain the reported decreased prima-
ry patency rate of forearm radial artery–to–antecu-
bital vein straight and loop PTFE dialysis grafts (46%
at 18 months), resulting in frequent thrombecto-
my.16,17
On the basis of these reports, we have little
enthusiasm to create forearm PTFE AVFs in patients
with diabetes and prefer construction of a more
durable upper-arm autogenous arteriovenous fistula.
The technical modifications for creation of TBAVFs
described herein include the use of a standardized
tunneling device to limit axial rotation, venography,
and surgical exposure through a single incision
rather than a separate incision for brachial artery
exposure, as has been previously described.11-13
These modifications have resulted in a 1.7% wound
infection rate, a mean operating time of 90 minutes
(range, 62 to 150 minutes), and minimal forearm
venous congestion.
In our experience, RCAVFs in patients without
diabetes displayed a 20% nonmaturation rate and an
80% 18-month primary patency rate, which are sig-
nificantly different than those in patients with dia-
betes (p < 0.05). Of the seven RCAVF failures that
were converted to BCAVFs (n = 3) and TBAVFs (n
= 4), nonmaturation and 18-month primary patency
rates were not significantly different than those for
BCAVFs (n = 19) and TBAVFs (n = 22). In addi-
tion, our 18-month primary patency estimates of
78% for BCAVFs and 79% for TBAVFs compare
favorably with those reported for patients without
diabetes (75% at 1 year; 85% at 19 months).8,12
Lastly, creation of an autogenous upper-arm
hemodialysis fistula as the initial access procedure
does not preclude subsequent placement of a PTFE
dialysis graft. In the present study, six patients who
had nonmaturing BCAVFs underwent creation of an
ipsilateral brachial artery–to–axillary vein PTFE
AVF. This approach has also been used after failed
TBAVFs.13
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